EC approve Zeposia® to treat ulcerative colitis
The European Commission (EC) has granted Zeposia® (ozanimod) a marketing…
The European Commission (EC) has granted Zeposia® (ozanimod) a marketing authorisation to treat people with ulcerative colitis.
List view / Grid view
The European Commission (EC) has granted Zeposia® (ozanimod) a marketing…
The European Commission (EC) has granted Zeposia® (ozanimod) a marketing authorisation to treat people with ulcerative colitis.
In the trial, 74 percent of participants responded to upadacitinib…
In the trial, 74 percent of participants responded to upadacitinib and 33 percent of patients achieved clinical remission.